Ki Hoon Lee

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Jennifer K. Litton, Sara A. Hurvitz, Lida A. Mina et al. · Annals of Oncology · 2020 · 394 citations · Full text

Medicine, Oncology, Pharmacology +14

Ferroelectrically tunable magnetic skyrmions in ultrathin oxide heterostructures

Lingfei Wang, Qiyuan Feng, Yoonkoo Kim et al. · Nature Materials · 2018 · 375 citations

Natural Sciences, Materials Science, Physics +14

A comparative study on the electrical conduction mechanisms of (Ba0.5Sr0.5)TiO3 thin films on Pt and IrO2 electrodes

Cheol Seong Hwang, Chang Seok Kang, Jin Won Kim et al. · Journal of Applied Physics · 1998 · 169 citations

Engineering, Materials Engineering, Materials Science +17

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

Johannes Ettl, Ruben G.W. Quek, Ki Hoon Lee et al. · Annals of Oncology · 2018 · 140 citations · Full text

Medicine, Oncology, Pharmacology +11

Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)

M. Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu et al. · Annals of Oncology · 2019 · 79 citations

Medicine, Oncology, Pharmacology +12